DDInter1082 DDInter1081
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label].
Lithium carbonate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Cisapride
Lithium carbonate {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lithium carbonate may lead to a major life threatening interaction when taken with Cisapride
Lithium carbonate may lead to a major life threatening interaction when taken with Ivosidenib